Epsilon M&A Deal Report - Syncrosome
Transaction Multiples for the Valuation of Private Companies
Etap / Syncrosome
No EMAT :
120415
Announced Date :
10/10/2023
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Etap
Target :
Syncrosome
Country :
Bouches-Du-Rhône
Sector of activity :
- Health, Pharmaceuticals & Biotechnology > Biotechnology
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Founded in 2000, Syncrosome is a CRO (Contract Research Organizations) specialising in preclinical in vivo pharmacology services focused on cardiovascular pathologies > Offers in vivo R&D services...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|||||
| Current |
Rating :
***
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biotechnology » = 43
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 37
| Date | Acquirer | Target | Country | Multiples | See details |
| 23/12/2024 | Private Group led by Andera Acto | Centre Azuréen de Cancérologie (CAC) | Alpes-Maritimes | * | 120397 |
| 04/02/2025 | Fagron | Guinama | Spain | ** | 120373 |
Source: Epsilon Research / EMAT
